These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 32853634)

  • 1. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
    Li K; Marano C; Zhang H; Yang F; Sandborn WJ; Sands BE; Feagan BG; Rubin DT; Peyrin-Biroulet L; Friedman JR; De Hertogh G
    Gastroenterology; 2020 Dec; 159(6):2052-2064. PubMed ID: 32853634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials.
    Li K; Strauss R; Marano C; Greenbaum LE; Friedman JR; Peyrin-Biroulet L; Brodmerkel C; De Hertogh G
    J Crohns Colitis; 2019 Aug; 13(8):1025-1035. PubMed ID: 30721964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis.
    Alsoud D; De Hertogh G; Compernolle G; Tops S; Sabino J; Ferrante M; Thomas D; Vermeire S; Verstockt B
    J Crohns Colitis; 2022 Nov; 16(10):1562-1570. PubMed ID: 35533353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.
    Christensen B; Hanauer SB; Erlich J; Kassim O; Gibson PR; Turner JR; Hart J; Rubin DT
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1557-1564.e1. PubMed ID: 28238954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sands BE; Sandborn WJ; Panaccione R; O'Brien CD; Zhang H; Johanns J; Adedokun OJ; Li K; Peyrin-Biroulet L; Van Assche G; Danese S; Targan S; Abreu MT; Hisamatsu T; Szapary P; Marano C;
    N Engl J Med; 2019 Sep; 381(13):1201-1214. PubMed ID: 31553833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
    Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
    United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
    Li K; Friedman JR; Chan D; Pollack P; Yang F; Jacobstein D; Brodmerkel C; Gasink C; Feagan BG; Sandborn WJ; Rutgeerts P; De Hertogh G
    Gastroenterology; 2019 Oct; 157(4):1019-1031.e7. PubMed ID: 31279870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
    Peyrin-Biroulet L; Loftus EV; Colombel JF; Danese S; Rogers R; Bornstein JD; Chen J; Schreiber S; Sands BE; Lirio RA
    Gastroenterology; 2021 Oct; 161(4):1156-1167.e3. PubMed ID: 34144047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological healing after infliximab induction therapy in children with ulcerative colitis.
    Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
    World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial.
    Yarur AJ; Chiorean MV; Panés J; Jairath V; Zhang J; Rabbat CJ; Sandborn WJ; Vermeire S; Peyrin-Biroulet L
    J Crohns Colitis; 2024 Jun; 18(6):885-894. PubMed ID: 38245818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is histological healing a feasible endpoint in ulcerative colitis?
    Rath T; Atreya R; Neurath MF
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):665-674. PubMed ID: 33481635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission.
    Rosenberg L; Nanda KS; Zenlea T; Gifford A; Lawlor GO; Falchuk KR; Wolf JL; Cheifetz AS; Goldsmith JD; Moss AC
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):991-6. PubMed ID: 23591275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes.
    Pandey A; Achrafie L; Kodjamanova P; Tencer T; Kumar J
    Curr Med Res Opin; 2022 Sep; 38(9):1531-1541. PubMed ID: 35608153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis.
    Ikeya K; Sugimoto K; Kawasaki S; Iida T; Maruyama Y; Watanabe F; Hanai H
    Dig Liver Dis; 2015 May; 47(5):365-71. PubMed ID: 25682993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Computer Vision to Improve Endoscopic Disease Quantification in Therapeutic Clinical Trials of Ulcerative Colitis.
    Stidham RW; Cai L; Cheng S; Rajaei F; Hiatt T; Wittrup E; Rice MD; Bishu S; Wehkamp J; Schultz W; Khan N; Stojmirovic A; Ghanem LR; Najarian K
    Gastroenterology; 2024 Jan; 166(1):155-167.e2. PubMed ID: 37832924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Histo-endoscopic Remission but not Endoscopic Healing Alone in Ulcerative Colitis is Associated with a Mucosal Transcriptional Profile Resembling Healthy Mucosa.
    Hernández-Rocha C; Nayeri S; Turpin W; Steel M; Borowski K; Stempak JM; Conner J; Silverberg MS
    J Crohns Colitis; 2022 Aug; 16(7):1020-1029. PubMed ID: 34999763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis.
    Parkes G; Ungaro RC; Danese S; Abreu MT; Arenson E; Zhou W; Ilo D; Laroux FS; Deng H; Sanchez Gonzalez Y; Peyrin-Biroulet L
    J Gastroenterol; 2023 Oct; 58(10):990-1002. PubMed ID: 37490069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.